Comparative Pharmacology
Head-to-head clinical analysis: TLANDO versus VIRILON.
Head-to-head clinical analysis: TLANDO versus VIRILON.
TLANDO vs VIRILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TLANDO (testosterone undecanoate) is an androgen that binds to and activates androgen receptors, leading to increased protein synthesis, muscle mass, bone density, and secondary sexual characteristics. Testosterone is converted to dihydrotestosterone (DHT) via 5α-reductase in target tissues, exerting both androgenic and anabolic effects.
Testosterone replacement therapy; binds to androgen receptors, leading to activation of androgen-responsive genes and promotion of male secondary sexual characteristics.
TLANDO (testosterone undecanoate) is administered orally. The recommended adult dose is 225 mg twice daily (approximately every 12 hours) with a meal containing fat. Swallow capsules whole; do not chew or crush.
200 mg intramuscularly every 2 weeks for androgen replacement therapy in adult males.
None Documented
None Documented
The terminal elimination half-life of testosterone is 10-100 minutes; however, for TLANDO (testosterone undecanoate) after oral administration, the apparent half-life is approximately 7-10 hours due to the slow release from chylomicrons and prolonged absorption.
Terminal elimination half-life is approximately 3–4 hours for methyltestosterone; however, the pharmacologic effect persists longer due to active metabolites, supporting once-daily dosing.
Approximately 90% of a dose is excreted in urine as glucuronide and sulfate conjugates of testosterone and its metabolites; about 6% is excreted in feces via bile. Unchanged testosterone accounts for less than 1% of urinary excretion.
Approximately 90% of administered methyltestosterone is excreted as glucuronide and sulfate conjugates in urine; less than 5% appears in feces as unchanged drug and metabolites.
Category C
Category C
Androgen/hormone replacement
Androgen